Abstract: Described herein are polyclonal and monoclonal antibodies that binds to VSIG3, compounds that modulate the interaction of VISTA and VSIG3, and methods of making and using the polyclonal and monoclonal antibodies and compounds. Also described herein are methods that include modulating the interaction of VISTA and VSIG3 by introducing a compound that modulates the interaction of VISTA and SIG3.

Abstract: An electronic device includes: a battery, a mainboard, and a housing. The battery is connected to the mainboard, the mainboard is provided with a first controller, the battery and the mainboard are installed in a cavity of the housing, and the housing includes a rear cover. The rear cover includes an electrochromic layer, the electrochromic layer is connected to the mainboard, the first controller is configured to control whether to power on the electrochromic layer, and a color displayed on the electrochromic layer when the electrochromic layer is powered on is different from a color displayed when the electrochromic layer is not powered on. The rear cover can change, by controlling a power-on and power-off status of the electrochromic layer, a color displayed on the electrochromic layer, and further change a color displayed on the rear cover, without changing a decorative film.

Abstract: The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.